Is there a specific date for apotex's ruxolitinib anda approval decision?

When can you expect Apotex's Ruxolitinib ANDA approval decision?

Apotex, a Canadian pharmaceutical company, has been working on an Abbreviated New Drug Application (ANDA) for Ruxolitinib, a treatment for certain types of myelofibrosis and polycythemia vera [1]. However, to date, no specific decision date has been announced by the FDA regarding the approval of Apotex's Ruxolitinib ANDA.

What's the status of Apotex's Ruxolitinib ANDA?

Apotex has been awaiting FDA approval for its Ruxolitinib ANDA since submitting the application, which included demonstrating bioequivalence to the brand-name medication, Jakafi [2][3].

Why is the patent expiration of Ruxolitinib significant?

The patent expiration of Ruxolitinib, held by Incyte Corporation, has been an essential consideration in the development and marketing of Apotex's Ruxolitinib ANDA [1]. Incyte filed patents around this product which have impacted generic manufacturers such as Apotex in gaining regulatory approval to the generic version for Ruxolitinib.

Can you still get generic Ruxolitinib?

Although not yet approved by the FDA, generic or biosimilar versions of Ruxolitinib might still become available as the patent for Jakafi expires or as new entrants enter the space before the exclusive protection ends.

Who holds the patent on Ruxolitinib?

Incyte Corporation has been the sole patent holder for Ruxolitinib, with patents set to expire around 2030, potentially making it easier for generic manufacturers to gain approval and enter the market.

Sources:

1. www.drugpatentwatch.com - Patent Expiration Date and Patent Application Data
2. www.drugpatentwatch.com - Bioequivalence and Clinical Trials Data
3. www.drugpatentwatch.com - Incyte’s Patent Portfolio Information.